Cognitive deficits associated with combined HIV gp120 expression and chronic methamphetamine exposure in mice

European Neuropsychopharmacology

Volumn 25, Issue 1, 2015, Pages 141-150

  Kesby, James P ^a   Markou, Athina ^a   Semenova, Svetlana ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Behavior; Recognition memory; Spatial learning; Transgenic

Indexed keywords

GLYCOPROTEIN GP 120; METHAMPHETAMINE; CENTRAL STIMULANT AGENT; GLIAL FIBRILLARY ACIDIC PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASSOCIATIVE MEMORY; BARNES MAZE TEST; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG EXPOSURE; EXECUTIVE FUNCTION; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEARNING; MALE; MEMORY CONSOLIDATION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RECOGNITION; SPATIAL LEARNING; WORKING MEMORY; ANALYSIS OF VARIANCE; ANIMAL; BODY WEIGHT; C57BL MOUSE; COGNITION DISORDERS; DISEASE MODEL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; MAZE TEST; METABOLISM; REACTION TIME; TRANSGENIC MOUSE; VISUAL ADAPTATION;

ADAPTATION, OCULAR; ANALYSIS OF VARIANCE; ANIMALS; BODY WEIGHT; CENTRAL NERVOUS SYSTEM STIMULANTS; COGNITION DISORDERS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; GLIAL FIBRILLARY ACIDIC PROTEIN; HIV ENVELOPE PROTEIN GP120; MALE; MAZE LEARNING; METHAMPHETAMINE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; REACTION TIME; RECOGNITION (PSYCHOLOGY);

EID: 84920481712     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2014.07.014     Document Type: Article

References (46)

1. Achim C.L., Adame A., Dumaop W., Everall I.P., Masliah E. Increased accumulation of intraneuronal amyloid β in HIV-infected patients. J. Neuroimmune Pharmacol. 2009, 4:190-199.
2. Barnes C.A. Memory deficits associated with senescence: a neurophysiological and behavioral study in the rat. J. Comp. Physiol. Psychol. 1979, 93:74-104.
3. Barker G.R.I., Warburton E.C. When is the hippocampus involved in recognition memory?. J. Neurosci. 2011, 31:10721-10731.
4. Barker G.R.I., Warburton E.C. Object-in-place associative recognition memory depends on glutamate receptor neurotransmission within two defined hippocampal-cortical circuits: a critical role for AMPA and NMDA receptors in the hippocampus, perirhinal, and prefronal cortices. Cerebral Cortex 2013, in press.
5. Barker G.R.I., Bird F., Alexander V., Warburton E.C. Recognition memory for objects, place, and temporal order: a disconnection analysis of the role of the medial prefrontal cortex and perirhinal cortex. J. Neurosci. 2007, 27:2948-2957.
6. Belcher A.M., Feinstein E.M., O'Dell S.J., Marshall J.F. Methamphetamine influences on recognition memory: comparison of escalating and single-day dosing regimens. Neuropsychopharmacology 2008, 33:1453-1463.
7. Berman S., O'Neill J., Fears S., Bartzokis G., London E.D. Abuse of amphetamines and structural abnormalities in the brain. Ann. NY Acad. Sci. 2008, 1141:195-220.
8. Bourin M., Hascoet M. The mouse light/dark box test. Eur. J. Pharmacol. 2003, 463:55-65.
9. Carey C.L., Woods S.P., Rippeth J.D., Gonzalez R., Heaton R.K., Grant I. Additive deleterious effects of methamphetamine dependence and immunosuppression on neuropsychological functioning in HIV infection. AIDS Behav. 2006, 10:185-190.
10. Chaouloff F., Durand M., Mormede P. Anxiety- and activity-related effects of diazepam and chlordiazepoxide in the rat light/dark and dark/light tests. Behav. Brain Res. 1997, 85:27-35.
11. Chana G., Everall I.P., Crews L., Langford D., Adame A., Grant I., Cherner M., Lazzaretto D., Heaton R., Ellis R., Masliah E. Cognitive deficits and degeneration of interneurons in HIV+ methamphetamine users. Neurology 2006, 67:1486-1489.
12. Chang L., Ernst T., Speck O., Grob C.S. Additive effects of HIV and chronic methamphetamine use on brain metabolite abnormalities. Am. J. Psychiatry 2005, 162:361-369.
13. Chen Y.J., Liu Y.L., Zhong Q., Yu Y.F., Su H.L., Toque H.A., Dang Y.H., Chen F., Xu M., Chen T. Tetrahydropalmatine protects against methamphetamine-induced spatial learning and memory impairment in mice. Neurosci. Bull. 2012, 28:222-232.
14. Clark R.E., Kuczenski R., Segal D.S. Escalating dose, multiple binge methamphetamine regimen does not impair recognition memory in rats. Synapse 2007, 61:515-522.
15. D'Hooge R., Franck F., Mucke L., De Deyn P.P. Age-related behavioural deficits in transgenic mice expressing the HIV-1 coat protein gp120. Eur. J. Neurosci. 1999, 11:4398-4402.
16. Eddleston M., Mucke L. Molecular profile of reactive astrocytes - implications for their role in neurological disease. Neuroscience 1993, 54:15-36.
17. Gorry P.R., Ong C., Thorpe J., Bannwarth S., Thompson K.A., Gatignol A., Wesselingh S.L., Purcell D.F.J. Astrocyte infection by HIV-1: mechanisms of restricted virus replication, and role in the pathogenesis of HIV-1-associated dementia. Curr. HIV Res. 2003, 1:463-473.
18. Grace C.E., Schaefer T.L., Herring N.R., Graham D.L., Skelton M.R., Gudelsky G.A., Williams M.T., Vorhees C.V. Effect of a neurotoxic dose regimen of (+)-methamphetamine on behavior, plasma corticosterone, and brain monoamines in adult C57BL/6 mice. Neurotoxicol. Teratol. 2010, 32:346-355.
19. Gray F., Lescs M.C., Keohane C., Paraire F., Marc B., Durigon M., Gherardi R. Early brain changes in HIV-infection: neuropathological study of 11 HIV seropositive, non-AIDS cases. J. Neuropathol. Exp. Neurol. 1992, 51:177-185.
20. Heaton R.K., Grant I., Butters N., White D.A., Kirson D., Atkinson J.H., McCutchan J.A., Taylor M.J., Kelly M.D., Ellis R.J., Wolfson T., Velin R., Marcotte T.D., Hesselink J.R., Jernigan T.L., Chandler J., Wallace M., Abramson I. The HNRC 500: neuropsychology of HIV infection at different disease stages. J. Int. Neuropsychol. Soc. 1995, 1:231-251.
21. Henry B.L., Geyer M.A., Buell M., Perry W., Young J.W., Minassian A. Behavioral effects of chronic methamphetamine treatment in HIV-1 gp120 transgenic mice. Behav. Brain Res. 2013, 236:210-220.
22. Izquierdo A., Belcher A.M., Scott L., Cazares V.A., Chen J., O'Dell S.J., Malvaez M., Wu T., Marshall J.F. Reversal-specific learning impairments after a binge regimen of methamphetamine in rats: possible involvement of striatal dopamine. Neuropsychopharmacology 2010, 35:505-514.
23. Jernigan T.L., Gamst A.C., Archibald S.L., Fennema-Notestine C., Mindt M.R., Marcotte T.L., Heaton R.K., Ellis R.J., Grant I. Effects of methamphetamine dependence and HIV infection on cerebral morphology. Am. J. Psychiatry 2005, 162:1461-1472.
24. Kesby J.P., Hubbard D.T., Markou A., Semenova S. Expression of HIV gp120 protein increases sensitivity to the rewarding properties of methamphetamine in mice. Addict. Biol. 2012, 19:593-605.
25. Krucker T., Toggas S.M., Mucke L., Siggins G.R. Transgenic mice with cerebral expression of human immunodeficiency virus type-1 coat protein gp120 show divergent changes in short- and long-term potentiation in CA1 hippocampus. Neuroscience 1998, 83:691-700.
26. Kuczenski R., Everall I.P., Crews L., Adame A., Grant I., Mashliah E. Escalating dose-multiple binge methamphetamine exposure results in degeneration of the neocortex and limbic system in the rat. Exp. Neurol. 2007, 207:42-51.
27. Langford D., Adame A., Grigorian A., Grant I., McCutchan J.A., Ellis R.J., Marcotte T.D., Masliah E. Patterns of selective neuronal damage in methamphetamine-user AIDS patients. J. Acquir. Immune Defic. Syndr. 2003, 34:467-474.
28. Lindl K.A., Marks D.R., Kolson D.L., Jordan-Sciutto K.L. HIV-associated neurocognitive disorder: pathogenesis and therapeutic opportunities. J. Neuroimmune Pharmacol. 2010, 5:294-309.
29. Marquez C., Mitchell S.J., Hare C.B., John M., Klausner J.D. Methamphetamine use, sexual activity, patient-provider communication, and medication adherence among HIV-infected patients in care, San Francisco 2004-2006. AIDS Care 2009, 21:575-582.
30. Masliah E., Ge N., Achim C.L., Hansen L.A., Wiley C.A. Selective neuronal vulnerability in HIV encephalitis. J. Neuropathol. Exp. Neurol. 1992, 51:585-593.
31. Masliah E., Heaton R.K., Marcotte T.D., Ellis R.J., Wiley C.A., Mallory M., Achim C.L., McCutchan J.A., Nelson J.A., Atkinson J.H., Grant I., Chandler J.L., Wallace M.R., Spector S.A., Jernigan T., Hesselink J., Hansen L., Abramson I., Masys D. Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders. Ann. Neurol. 1997, 42:963-972.
32. Melrose R.J., Tinaz S., Castelo J.M.B., Courtney M.G., Stern C.E. Compromised fronto-striatal functioning in HIV: an fMRI investigation of semantic event sequencing. Behav. Brain Res. 2008, 188:337-347.
33. Nath A. Human immunodeficiency virus-associated neurocognitive disorder pathophysiology in relation to drug addiction. Addiction Reviews 2 2010, 122-128. Wiley, Hoboken. G.R. Uhl (Ed.).
34. Navia B.A., Cho E.S., Petito C.K., Price R.W. The AIDS dementia complex: 2. Neuropathology. Ann. Neurol. 1986, 19:525-535.
35. Nordahl T.E., Salo R., Leamon M. Neuropsychological effects of chronic methamphetamine use on neurotransmitters and cognition: a review. J. Neuropsychiatry Clin. Neurosci. 2003, 15:317-325.
36. Paylor R., Zhao Y.G., Libbey M., Westphal H., Crawley J.N. Learning impairments and motor dysfunctions in adult Lhx5-deficient mice displaying hippocampal disorganization. Physiol. Behav. 2001, 73:781-792.
37. Reichel C.M., Ramsey L.A., Schwendt M., McGinty J.F., See R.E. Methamphetamine-induced changes in the object recognition memory circuit. Neuropharmacology 2012, 62:1119-1126.
38. Rippeth J.D., Heaton R.K., Carey C.L., Marcotte T.D., Moore D.J., Gonzalez R., Wolfson T., Grant I. Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J. Int. Neuropsychol. Soc. 2004, 10:1-14.
39. Roberts A.J., Maung R., Sejbuk N.E., Ake C., Kaul M. Alteration of methamphetamine-induced stereotypic behaviour in transgenic mice expressing HIV-1 envelope protein gp120. J. Neurosci. Methods 2010, 186:222-225.
40. Scott J.C., Woods S.P., Matt G.E., Meyer R.A., Heaton R.K., Atkinson J.H., Grant I. Neurocognitive effects of methamphetamine: a critical review and meta-analysis. Neuropsychol. Rev. 2007, 17:275-297.
41. Stubbe-Drager B., Deppe M., Mohammadi S., Keller S.S., Kugel H., Gregor N., Evers S., Young P., Ringelstein E.B., Arendt G., Knecht S., Husstedt I.W. Early microstructural white matter changes in patients with HIV: a diffusion tensor imaging study. BMC Neurol. 2012, 12:23.
42. Toggas S.M., Masliah E., Rockenstein E.M., Rall G.F., Abraham C.R., Mucke L. Central-nervous-system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature 1994, 367:188-193.
43. Toneatto S., Finco O., van der Putten H., Abrignani S., Annunziata P. Evidence of blood-brain barrier alteration and activation in HIV-1 gp120 transgenic mice. AIDS 1999, 13:2343-2348.
44. Vitkovic L., daCunha A. Role for astrocytosis in HIV-1-associated dementia. HIV and Dementia 1995, 105-116. Springer-Verlag, Berlin. M.B. Oldstone, L. Vitkovic (Eds.).
45. Weis S., Haug H., Budka H. Astroglial changes in the cerebral-cortex of AIDS brains - a morphometric and immunohistochemical investigation. Neuropathol. Appl. Neurobiol. 1993, 19:329-335.
46. Zhu T., Zhong J.H., Hu R., Tivarus M., Ekholm S., Harezlak J., Ombao H., Navia B., Cohen R., Schifitto G. Patterns of white matter injury in HIV infection after partial immune reconstitution: a DTI tract-based spatial statistics study. J. Neurovirol. 2013, 19:10-23.